Main outcome measures:
Thyroid function and anatomical aspect (volume, echogenicity and echostructure) were measured.
Results:
In group "A", five children developed thyroidal hypothyroidism characterized by persistently elevated TSH concentrations and exaggerated TSH responses after TRH stimulation. In the majority of patients in groups "A" and "C", thyroid echogenicity and volume were decreased, and the echostructure was inhomogeneous. Thyroid ultrasound imaging was normal in group "B" children.
Conclusions:
Inadequately treated maternal Graves' disease not only may lead to CH-C but also carries an, until now, unrecognized risk of thyroid disintegration in the offspring as well. The authors speculate that insufficient TSH secretion due to excessive maternal-fetal thyroid hormone transfer inhibits physiological growth and development of the child's thyroid.
COMMENT
Central congenital hypothyroidism (CH-C) is a rare condition only described a few years ago. When not a part of congenital multiple pituitary hormone deficiencies, CH-C is characterized by neonatal hypopituitary hypothyroidism associated with maternal thyrotoxicosis, and it is considered to result from fetal pituitary suppression due to elevated thyroid hormone levels in the mother. The infants are diagnosed by their low serum T4 levels -at neonatal screening for CH -and are treated with l-T4. CH-C is considered to be transient, and these infants are usually withdrawn from l-T4 supplementation after a few months. The present study was initiated after the authors had observed (after l-T4 withdrawal) persistent thyroid dysfunction in some of them. Group "A" comprised 19 infants born to mothers with inadequately treated Graves' disease with elevated serum free T 4 (>2.5 ng/dl) and a suppressed TSH. Before initiating l-T4 supplementation, neonatal free T 4 levels were low (< 0.93 ng/dl) and serum TSH also -inappropriately -low (0.1-7.5 µU/ml). After withdrawal of l-T4 supplementation, 5 infants had persistent TSH elevation, 4 infants had transient TSH elevation and finally 4 infants had normal serum TSH. Group "B" comprised 6 infants born to mothers with "adequately" treated Graves' disease (either cured or treated with ATD); neonatal thyroid function was normal in all 6 children. One of the interesting -and novel -features of present study was to show the presence of frequent abnormalities (probably irreversible) in the ultrasound pattern in infants of group "A", with a reduced echogenicity and inhomogeneous echostructure, at ages between 1.1 & 8.5 years. The main message of this extensive follow-up study of children born with CH-C, due to inadequately treated maternal Graves' disease, was to show that there is a risk of persistent thyroid function abnormalities in the offspring. While the neonatal pituitary dysfunction improved after birth, 5 of these infants developed primary hypothyroidism during childhood, with persisting hyperthyrotropinemia, exaggerated TSH response to TRH stimulation, and thyroid glands with small volume and inhomogeneous echostructure. The authors attribute this disease entity to the consequences of CH-C, although they cannot rule out the possibility of a detrimental role of maternal antibodies during pregnancy on the development of the fetal thyroid gland (for instance blocking TSH-receptor auto-antibodies could lead to an abnormal thyroidal development). Long term follow-up is needed to evaluate the incidence and further consequences of this novel pathological entity, and to define the most appropriate diagnostic and therapeutic approach. In the mean time, careful monitoring of maternal thyroid function is highly recommended in mothers with active Graves' disease, as well as a careful follow-up of children born to such mothers, including thyroid function determination and imaging by ultrasound. See Table below 
